AstraZeneca licenses respiratory drug to Insmed

October 5, 2016 11:31 AM

2 0

AstraZeneca licenses respiratory drug to Insmed

Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.

AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said.

Also read: EFG International says to cut up to 450 jobs in BSI integration

Read more

To category page

Loading...